-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Leadman (300289.SZ) announced that the company recently learned that the recombinant B-group meningococcal vaccine (Escherichia coli) (“recombinant group B meningococcal vaccine”) independently developed by the holding subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (“Xiansheng Xiangrui”) has begun phase I clinical trials at the Hunan Provincial Center for Disease Prevention and Control.
Share
Listen to the news
Zhitong Finance App News, Leadman (300289.SZ) announced that the company recently learned that the recombinant B-group meningococcal vaccine (Escherichia coli) (“recombinant group B meningococcal vaccine”) independently developed by the holding subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (“Xiansheng Xiangrui”) has begun phase I clinical trials at the Hunan Provincial Center for Disease Prevention and Control.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending